🇺🇸

US SEC Filing Intelligence

· daily

US Corporate Distress Financial Stress SEC Filings — April 10, 2026

Across 35 8-K filings in the USA Corporate Distress & Bankruptcy stream (April 10, 2026 period), distress signals dominate with 8 companies facing Nasdaq delisting risks due to sub-$1 bid prices (e.g., DevvStream, Beyond Air, SCWorx), low stockholders' equity (Caring Brands, Callan JMB), or MVLS/net income failures (Alpha Modus), reflecting microcap vulnerability amid no explicit YoY/QoQ declines but inferred weak performance from compliance breaches post-reverse splits. Countervailing trends include 12+ capital raises/ATM offerings/debt amendments (e.g., Spire Global $70M PP, Annovis $10M offering, CoreCivic revolver to $400M), signaling aggressive liquidity pursuits to avert bankruptcy. No outright bankruptcies or going-concern warnings, but lease terminations (Lyra Therapeutics $4.4M cost) and deal terminations (Dynamix SPAC) highlight cost-cutting/restructuring. Positive outliers like Hecla Mining's $263M debt redemption and Venture Global's $1.75B refinancing unlock flexibility, while mixed sentiments prevail (14/35 neutral/mixed). Portfolio-level pattern: 40% filings show financing activity vs. 23% delisting risks, with no insider trading or dividend/buyback data but forward catalysts clustered April 10-15 closings. Implications: Short-term volatility in Nasdaq microcaps; opportunities in refinancings for turnaround plays.

35 high priority 35 total filings
· daily

US Executive Officer Management Changes SEC — April 10, 2026

Across 39 filings on executive and director changes dated April 10, 2026, the dominant theme is board refreshment with 14 directors announcing non-re-election or retirement (e.g., NexMetals, Expand Energy, Cypherpunk's 4 directors), typically without disagreements, signaling proactive governance amid 2026 AGMs. Positive appointments of seasoned executives dominate in energy/mining (NexMetals' Rio Tinto vet, Royale's petroleum geologist), tech/fintech (Remitly's ex-Twitter CTO), and industrials (Caterpillar's internal CFO successor post-record $67.6B FY2025 sales), boosting sentiment in 9 cases. Retention and amended agreements (Immunic CEO bonus $670K, Longeveron RSU grants post-financing, Playboy RSUs vesting 2027-2028) highlight efforts to retain talent amid transitions, with 7 CFO/PAO changes (e.g., Expand, Kalaris, Regional Health) mostly neutral but interim leadership in smaller firms raising execution risks. No broad period-over-period deteriorations noted, but sector-specific strengths emerge like Caterpillar's YoY sales records vs. biotech churn (Vir, Immunic). Capital allocation leans toward equity incentives (PodcastOne plan doubled to 4M shares, Cherry Hill LTIP $900K target for CEO), with no dividend/buyback shifts. Overall, low materiality (avg 5.5/10) suggests limited immediate volatility, but clustered AGMs and C-suite handovers create near-term catalysts for governance scrutiny and stock reactions.

39 high priority 39 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 10, 2026

Across 39 filings on USA Board Room Changes from April 10, 2026, dominant themes include board refreshment via retirements/non-re-elections (17 cases, e.g., NexMetals, Cypherpunk, Expand Energy) and new appointments of experienced executives/directors (12 cases, e.g., Remitly, Humana, Caterpillar), with neutral sentiment prevailing (70% of filings) signaling routine transitions rather than distress. Positive signals emerge in strategic hires like Remitly's ex-Twitter CTO and Caterpillar's internal CFO succession amid record $67.6B FY2025 sales, while mixed/negative notes in biotech (Immunic CEO transition, Vir Biotech CMO exit) highlight commercialization pivots. No widespread period-over-period deteriorations noted, but capital allocation trends show increased equity incentives (RSUs/options in 10 filings, e.g., PodcastOne doubling share pool to 4M, Longeveron restoring salaries + 250k-500k RSUs post-financing). Executive retention/transition packages (9 cases, e.g., Bruker $1M severance, Hawaiian Electric $200k/mo consulting) indicate stability focus amid talent wars. Portfolio-level implication: Biotech/healthcare sees highest churn (10/39, avg materiality 6.5/10), REITs emphasize comp benchmarking (Cherry Hill, Innovative Industrial), with AGMs cluster in May-June 2026 as catalysts. Overall, low disruption risk but watch for post-AGM board impacts on strategy.

39 high priority 39 total filings
· daily

US Merger & Acquisition SEC Filings — April 10, 2026

The 14 filings reveal a surge in SPAC activity with 5 new IPOs/extensions/appointments signaling renewed M&A appetite in blank-check vehicles targeting tech, private credit, and advanced materials, amid 3 director resignations and 1 delisting highlighting sector churn. Actual M&A progressed with BiomX's acquisition of Zorronet (AI defense tech) from Nukkleus, FG Merger's Boxabl deal extension to July 31, 2026, and Compass Digital's merger with Key Mining, while Ashford Hospitality's $40.5M hotel sale improved pro forma operating income 18.5% YoY to $137.9M and narrowed net loss 10.7% to $(191.8M). Jet.AI's 1-for-200 reverse split reduced shares 99.5% to maintain Nasdaq compliance, freeing shares for potential future deals. No broad insider trading activity noted, but board additions in Iron Horse, T-REX convey management conviction; sentiments skew positive/neutral (10/14) with SPAC governance tweaks dominating. Portfolio-level trends show asset sales/debt reductions enhancing balance sheets (e.g., Ashford net debt -1.6% pro forma), positioning for M&A catalysts. Distressed signals in Quetta (MVLS failure post-180 days) contrast bullish IPO momentum ($350M+ raised), implying selective opportunities in dealflow-ready SPACs vs. fading ones.

14 high priority 14 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 10, 2026

Overnight SEC filings highlight a surge in proxy statements (15+ filings) signaling peak proxy season with AGMs clustered in May-June 2026, alongside active M&A/SPAC activity (McCormick-Unilever combo, Willow Lane-Boost Run, Constellation-HiTech) promising synergies and listings. Energy/mining sectors show deleveraging strength: Hecla redeemed $263M notes for unencumbered balance sheet, Riley cut debt 32% post-acquisitions with equity +22% YoY and $100M buyback. Financial results mixed: Li Auto revenues -22.3% YoY and NI -86% YoY, Qudian revenues -81.1% YoY despite NI +673% on non-op income, contrasting Welltower's 14.1% YoY NOI growth and 228.2% cumulative TSR 2021-2025. Capital allocation favors shareholders with dividend hikes (Riley +5%, Welltower +10.4%) and buybacks (News Corp $1B program, Riley $100M). No widespread insider selling patterns, but board refreshers indicate governance focus; forward catalysts include earnings previews and de-SPAC closings H2 2026. Portfolio trend: Positive sentiment dominates (25+ bullish/neutral), with outliers in China-exposed autos/fintech dragging, implying overweight energy/REITs ahead of catalysts.

27 high priority 23 medium 50 total filings
· daily

Biotech Small-Cap Approvals — April 09, 2026

The FDA approved 17 other products from April 2-6, 2026, with 0 NMEs, 0 biosimilars, 0 label expansions, and all 17 neutral signals in the biotech small-cap stream. A clear dominant theme emerges from clustering: 9 approvals for dapagliflozin across Alembic, Aurobindo Pharma, Micro Labs, Ajanta Pharma Ltd, Macleods Pharms Ltd, Lupin Ltd, Torrent, MSN, and Cipla, alongside 3 approvals for nintedanib esylate by Cipla, Dr Reddys, and Sandoz. Highest-conviction signal is the dapagliflozin cluster (e.g., Cipla and Lupin Ltd approvals), representing bullish entry opportunities for these small-cap generic sponsors into a mature market, balanced by originator revenue erosion risks. Additional singles include glycopyrronium tosylate (Padagis US), phenylephrine hydrochloride (Baxter Hlthcare Corp), and three unknowns (Sandoz Inc, Biocon Pharma Ltd, Inventia Hlthcare). Key risk/watch item: intense multi-sponsor competition in dapagliflozin and nintedanib, potentially compressing entrant margins despite neutral signals.

17 total filings
· daily

New Drug Approvals (Original) — April 09, 2026

The FDA recorded 17 'Other' new drug approvals from April 2-6, 2026 (period defined as April 9), comprising 0 NMEs, 0 biosimilars, 0 label expansions per mix breakdown, with all individual analyses labeled as neutral fallback biosimilar approvals and lacking commercial data. A clear dominant theme emerges in clustered generic/biosimilar entries for dapagliflozin (9 approvals to Alembic, Aurobindo Pharma, Micro Labs, Ajanta Pharma Ltd, Macleods Pharms Ltd, Lupin Ltd, Torrent, MSN, Cipla) and nintedanib esylate (3 approvals to Cipla, Dr Reddys, Sandoz), signaling heightened competition in cardiorenal-metabolic and idiopathic pulmonary fibrosis markets. Highest-conviction signal is the dapagliflozin cluster, bullish for entrant sponsors like Cipla and Lupin Ltd as execution signals in complex generics, bearish for originator AstraZeneca with potential 30-60% Farxiga revenue erosion over 2-3 years. Additional singles include glycopyrronium tosylate (Padagis US), phenylephrine hydrochloride (Baxter Hlthcare Corp), and three unknowns (Sandoz Inc, Biocon Pharma Ltd, Inventia Hlthcare). Key risk/watch item: competitive intensification from multiple dapagliflozin entrants, monitor originator revenue trajectories and generic launch timelines.

17 total filings
· daily

Federal Construction & Infrastructure Contracts — April 09, 2026

These two civilian federal construction contracts total $218,304,799 in obligations, with 0/2 defense-related and focus on Department of Transportation (DOT) and Department of Homeland Security (DHS) infrastructure projects. The highest materiality award is a bullish $95,538,222 firm fixed price delivery order to Brasfield & Gorrie LLC from the U.S. Coast Guard for utility infrastructure, roads, and clinic construction at USCG Base Charleston, SC, signaling substantial medium-term revenue under full and open competition. Kokosing Construction Company, Inc. received a neutral $122,766,577 contract modification from DOT, lacking detailed competitive or risk signals. Dominant theme is civilian agency infrastructure buildout with no defense exposure. Highest-conviction signal is bullish growth for Brasfield & Gorrie amid 3.25-year performance period starting April 2026. Key watch item is Brasfield & Gorrie's outlay progress from $0 current amid high firm fixed price execution risk.

2 total filings
· daily

DHS Homeland Security Contracts — April 09, 2026

DHS awarded $152,669,403 in obligations across two civilian contracts during April 09-09, 2026, with zero defense-related activity. The dominant theme is U.S. Coast Guard infrastructure investment, led by a $95.5 million firm fixed-price design-build contract to Brasfield & Gorrie LLC for utility, roads, and clinic construction at USCG Base Charleston, SC. This full and open competition award provides the highest-conviction bullish signal for Brasfield & Gorrie, estimating ~$29 million annual revenue over 3.25 years starting April 2026. A neutral $57.1 million modification to Paragon Professional Services LLC adds lesser materiality. Key watch item: Brasfield & Gorrie's outlay progress from $0 current obligation amid high firm fixed-price execution risk.

2 total filings
· daily

VA Healthcare & Services Contracts — April 09, 2026

SALIENT CRGT, INC. was awarded a single $205,535,562 firm fixed price Delivery Order by the Department of Veterans Affairs' Technology Acquisition Center NJ for IT network engineering and support services, comprising 100% civilian VA Healthcare & Services obligations with 0 defense-related contracts. The neutral signal (6/10 strength, 7/10 materiality) reflects a competitive full and open win under NAICS 541512, with $101,120,213 already outlayed over ~3 years of the ~5-year period ending 2026-06-21 (potential 2026-09-21), implying ~$41M annual revenue. Substantial subcontracting ($269,012,748 across 43 subawards exceeding prime obligation) tempers direct revenue capture. Highest-conviction signal is established revenue visibility from outlays. Key risk is high pricing risk on the firm fixed price structure amid elevated subawards.

1 total filings
· daily

New Federal Contractors — April 09, 2026

This digest covers 12 new federal contractor awards totaling $1,755,742,802 in obligations from April 9, 2026, with only 1/12 defense-related (CACI's GSA network defense IT contract) and the rest civilian-focused across GSA, VA, NASA, DHS, Treasury, Commerce, and State. Dominant themes include IT systems design and network support, led by GSA and VA with multi-year delivery orders emphasizing cybersecurity and cloud migration. Highest-conviction bullish signal is CACI, Inc. - Federal's $708M cost-plus award for federal enterprise network defense, signaling low-risk revenue through 2024 despite negative outlays to date. Key risk is execution uncertainty from $0 outlays on recent awards like Brasfield & Gorrie LLC's $95.5M DHS construction (starts 2026) and Integral Federal's $61M State printing equipment contract.

12 total filings
· daily

Significant Contract Modifications ($10M+) — April 09, 2026

These 12 significant contract modifications totaling $1,755,742,802 in obligations over April 09, 2026, are overwhelmingly civilian-focused with only 1/12 defense-related, dominated by IT systems design and support services across GSA, VA, NASA, and DHS. Highest-conviction bullish signal is CACI, INC. - FEDERAL's $708M GSA award for federal enterprise network defense, providing low-risk cost-plus revenue through 2024-04-30 despite negative outlays to date. Deloitte Consulting LLP stands out with dual wins totaling $202M from GSA and Treasury for cloud migration and management consulting. Key risk is execution on zero or negative outlays across multiple awards including Brasfield & Gorrie ($96M DHS), Integral Federal ($61M State), and Satsyil ($62M Commerce), signaling potential delays in revenue recognition.

12 total filings
· daily

Contract Deobligations Alert — April 09, 2026

Across 12 contract deobligations alerts totaling $1,755,742,802 in obligations, only 1/12 is defense-related (CACI's GSA network defense award), with the remainder skewed toward civilian agencies including GSA, VA, NASA, DHS, Treasury, Commerce, and State. Dominant themes center on IT systems design, network support, cloud migration, and professional services in civilian sectors, underscoring stable multi-year revenue for tech and consulting firms. Highest-conviction bullish signal is CACI International Inc's $708M GSA delivery order for federal enterprise network defense, with low-risk cost-plus structure despite negative outlays. Key risk is widespread $0 outlays on recent awards like Brasfield & Gorrie LLC's $95M DHS construction and Integral Federal Inc's $61M State printing equipment contracts, signaling potential execution delays amid deobligations. Watch subaward execution exceeding primes (e.g., Salient CRGT Inc's $269M subawards vs. $205M obligation) for margin pressure.

12 total filings
· daily

Contract Option Exercises — April 09, 2026

These 12 contract option exercises totaling $1,755,742,802 in obligations (1/12 defense-related, 11/12 civilian) highlight civilian agency dominance, with GSA, VA, NASA, and DHS leading IT services, engineering support, and construction awards. Dominant themes include federal IT network defense and cloud migration, exemplified by CACI's $708M GSA award as the highest-conviction bullish signal for stable, low-risk revenue through 2024. Deloitte Consulting LLP shows concentration with $202M across GSA and Treasury wins, signaling consulting strength. Key risk is execution uncertainty from negative outlays (CACI -$453K) and zero outlays on fresh awards like Brasfield & Gorrie ($95M DHS) starting 2026. Watch multi-year performance ends in 2026-2029 for option exercises and funding progress.

12 total filings
· daily

Federal Professional Services Contracts — April 09, 2026

These two civilian federal professional services contracts total $213,317,405 in obligations, with zero defense-related awards, highlighting NASA and Treasury Department spending on engineering and management consulting. HALVIK, LLC secured the highest-materiality award at $132,970,632 from NASA for enterprise-wide procurement support, a neutral signal as an 8(a) set-aside win with $102.4M already outlayed. Deloitte Consulting LLP's $80,346,773 Treasury BPA call for intelligence analysis is the highest-conviction bullish signal, reflecting strong execution with $62.6M outlayed in a full-and-open competition firm-fixed-price vehicle. Dominant theme is sustained civilian agency demand for support services amid ongoing performance through 2026. Key watch item: track option exercises for both contracts toward ceilings of $148.8M (HALVIK) and $101.3M (Deloitte) to gauge revenue upside.

2 total filings
· daily

Federal IT & Cybersecurity Contracts — April 09, 2026

Four federal IT and cybersecurity contracts totaling $1,097,635,237 in obligations, with 1/4 defense-related, highlight civilian agency dominance via GSA awards comprising ~75% of value ($830M to CACI and Deloitte). Highest-conviction bullish signal is CACI International Inc's $708M GSA cost-plus network defense delivery order, signaling low-risk multi-year revenue stability. VA and Commerce add neutral signals via Salient CRGT ($206M) and Satsyil Corp ($62M) for IT infrastructure and data services. Dominant theme is sustained civilian IT modernization amid cloud migration and network support needs. Key watch item: outlay progress across contracts, including CACI's negative $-453K and Satsyil's $0 outlays, amid option exercises and 2024-2030 end dates.

4 total filings
· daily

Mega Contracts Monitor ($100M+) — April 09, 2026

This week's Mega Contracts Monitor captures $1,291,393,992 in total obligations across 5 awards, with 1 defense-related and 4 civilian-focused contracts emphasizing federal IT services. GSA dominates with two high-value awards to CACI ($708M) and Deloitte ($122M), signaling robust demand for network defense and cloud migration in civilian agencies like GSA, VA, NASA, and DOT. The highest-conviction bullish signal is CACI's $708M cost-plus GSA delivery order for enterprise network defense, offering low-risk multi-year revenue through 2024. Neutral signals prevail in VA, NASA, and DOT contracts, with balanced execution via significant outlays in Salient CRGT ($101M) and Halvik ($102M). Key risk: Negative or low outlays in top materiality contracts like CACI (-$453k) and Deloitte (-$10k), warranting watch on spending progress amid potential adjustments.

5 total filings
· daily

High-Value Federal Grants ($5M+) — April 09, 2026

These 12 high-value federal contracts total $1,755,742,802 in obligations, with only 1/12 defense-related (CACI's GSA network defense award) and the remaining 11 civilian-focused across agencies like GSA, VA, NASA, DHS, Treasury, Commerce, and State. Dominant theme is multi-year IT systems design, network support, and professional services, led by CACI ($708M), SALIENT CRGT ($206M VA), and HALVIK ($133M NASA). Highest-conviction bullish signal is CACI's $708M cost-plus GSA delivery order for federal enterprise network defense, offering low-risk ~$141M annual revenue through 2024 with potential $1.03B ceiling. Balanced by neutral signals on most awards; key risk is stalled outlays, including CACI's negative $-453K and zero outlays on $368M+ across Brasfield & Gorrie ($96M DHS), SATSYIL ($62M Commerce), Integral Federal ($61M State), and ATT Mobility ($54M State).

12 total filings
· daily

General Federal Contracts — April 09, 2026

Across 12 contracts totaling $1,755,742,802 in obligations from April 09, 2026 data, only 1/12 is defense-related (CACI's GSA network defense award), with the remainder dominated by civilian agencies including GSA, VA, NASA, DHS, Treasury, Commerce, and State. IT services and support emerge as the dominant sector theme, comprising high-materiality awards like CACI's $708M and SALIENT CRGT's $206M. Highest-conviction bullish signal is CACI International Inc's $708M GSA cost-plus award for federal enterprise network defense, offering low-risk multi-year revenue despite negative outlays to date. Key risk is execution on firm-fixed-price contracts like Brasfield & Gorrie's $96M DHS construction award, carrying high pricing risk with $0 outlayed and performance starting 2026-04-20.

12 total filings
· daily

All NASA Contracts — April 09, 2026

NASA dominates this $132,970,632 obligation period with a single high-materiality award to HALVIK, LLC, representing 100% civilian exposure and 0% defense-related contracts. The dominant theme is NASA enterprise-wide procurement support services under an 8(a) competed set-aside delivery order. Highest-conviction signal is neutral, reflecting steady outlays of $102.43M to date on this cost-plus award fee vehicle with low pricing risk. HALVIK, a private 8(a)/EDWOSB firm, benefits from $58.86M in subawards across 48 recipients, but the contract nears its current 2026-04-30 end date. Key watch item: progress toward full $148.76M base-plus-options value and potential extension to 2026-11-30.

1 total filings